Literature DB >> 28669924

Histone H3 lysine 4 methyltransferase KMT2D.

Eugene Froimchuk1, Younghoon Jang1, Kai Ge2.   

Abstract

Histone-lysine N-methyltransferase 2D (KMT2D), also known as MLL4 and MLL2 in humans and Mll4 in mice, belongs to a family of mammalian histone H3 lysine 4 (H3K4) methyltransferases. It is a large protein over 5500 amino acids in size and is partially functionally redundant with KMT2C. KMT2D is widely expressed in adult tissues and is essential for early embryonic development. The C-terminal SET domain is responsible for its H3K4 methyltransferase activity and is necessary for maintaining KMT2D protein stability in cells. KMT2D associates with WRAD (WDR5, RbBP5, ASH2L, and DPY30), NCOA6, PTIP, PA1, and H3K27 demethylase UTX in one protein complex. It acts as a scaffold protein within the complex and is responsible for maintaining the stability of UTX. KMT2D is a major mammalian H3K4 mono-methyltransferase and co-localizes with lineage determining transcription factors on transcriptional enhancers. It is required for the binding of histone H3K27 acetyltransferases CBP and p300 on enhancers, enhancer activation and cell-type specific gene expression during differentiation. KMT2D plays critical roles in regulating development, differentiation, metabolism, and tumor suppression. It is frequently mutated in developmental diseases, such as Kabuki syndrome and congenital heart disease, and various forms of cancer. Further understanding of the mechanism through which KMT2D regulates gene expression will reveal why KMT2D mutations are so harmful and may help generate novel therapeutic approaches. Published by Elsevier B.V.

Entities:  

Keywords:  Enhancer; Epigenetic regulation; Gene expression; H3K4 methylation; H3K4 methyltransferase; KMT2D; MLL4

Mesh:

Substances:

Year:  2017        PMID: 28669924      PMCID: PMC5546304          DOI: 10.1016/j.gene.2017.06.056

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  66 in total

1.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

Review 2.  Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.

Authors:  Rajesh C Rao; Yali Dou
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

3.  Structure and expression pattern of human ALR, a novel gene with strong homology to ALL-1 involved in acute leukemia and to Drosophila trithorax.

Authors:  R Prasad; A B Zhadanov; Y Sedkov; F Bullrich; T Druck; R Rallapalli; T Yano; H Alder; C M Croce; K Huebner; A Mazo; E Canaani
Journal:  Oncogene       Date:  1997-07-31       Impact factor: 9.867

4.  Identification of the MLL2 complex as a coactivator for estrogen receptor alpha.

Authors:  Rigen Mo; Sambasiva M Rao; Yi-Jun Zhu
Journal:  J Biol Chem       Date:  2006-04-07       Impact factor: 5.157

Review 5.  Modification of enhancer chromatin: what, how, and why?

Authors:  Eliezer Calo; Joanna Wysocka
Journal:  Mol Cell       Date:  2013-03-07       Impact factor: 17.970

6.  Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases.

Authors:  Sunhwa Hong; Young-Wook Cho; Li-Rong Yu; Hong Yu; Timothy D Veenstra; Kai Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

7.  Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.

Authors:  Kristel M Dorighi; Tomek Swigut; Telmo Henriques; Natarajan V Bhanu; Benjamin S Scruggs; Nataliya Nady; Christopher D Still; Benjamin A Garcia; Karen Adelman; Joanna Wysocka
Journal:  Mol Cell       Date:  2017-05-05       Impact factor: 17.970

8.  Mutation of cancer driver MLL2 results in transcription stress and genome instability.

Authors:  Theodoros Kantidakis; Marco Saponaro; Richard Mitter; Stuart Horswell; Andrea Kranz; Stefan Boeing; Ozan Aygün; Gavin P Kelly; Nik Matthews; Aengus Stewart; A Francis Stewart; Jesper Q Svejstrup
Journal:  Genes Dev       Date:  2016-02-15       Impact factor: 11.361

9.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

10.  Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.

Authors:  Jiyuan Zhang; David Dominguez-Sola; Shafinaz Hussein; Ji-Eun Lee; Antony B Holmes; Mukesh Bansal; Sofija Vlasevska; Tongwei Mo; Hongyan Tang; Katia Basso; Kai Ge; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nat Med       Date:  2015-09-14       Impact factor: 53.440

View more
  91 in total

1.  FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.

Authors:  Rizwan Saffie; Nan Zhou; Delphine Rolland; Özlem Önder; Venkatesha Basrur; Sydney Campbell; Kathryn E Wellen; Kojo S J Elenitoba-Johnson; Brian C Capell; Luca Busino
Journal:  Cancer Res       Date:  2020-04-29       Impact factor: 12.701

2.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

3.  Epigenetic Mechanisms of Angiogenesis in the Ischemic Heart Diseases with Acupuncture Treatment.

Authors:  Hao Hong; Jun-Ming Yue; Wen-Jing Zhang; Bing-Mei Zhu
Journal:  Med Acupunct       Date:  2020-12-16

4.  Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.

Authors:  Shidong Lv; Haoran Wen; Xiongwei Shan; Jianhua Li; Yaobin Wu; Xinpei Yu; Wenhua Huang; Qiang Wei
Journal:  Epigenetics       Date:  2019-06-28       Impact factor: 4.528

5.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

6.  Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome.

Authors:  Giovanni A Carosso; Leandros Boukas; Jonathan J Augustin; Ha Nam Nguyen; Briana L Winer; Gabrielle H Cannon; Johanna D Robertson; Li Zhang; Kasper D Hansen; Loyal A Goff; Hans T Bjornsson
Journal:  JCI Insight       Date:  2019-10-17

7.  UBE3A Suppresses Overnutrition-Induced Expression of the Steatosis Target Genes of MLL4 by Degrading MLL4.

Authors:  Janghyun Kim; Bora Lee; Dae-Hwan Kim; Jae Gwang Yeon; Jeongkyung Lee; Younjung Park; Yuna Lee; Soo-Kyung Lee; Seunghee Lee; Jae W Lee
Journal:  Hepatology       Date:  2019-02-07       Impact factor: 17.425

Review 8.  Leveraging Genomics for Head and Neck Cancer Treatment.

Authors:  J D Kemmer; D E Johnson; J R Grandis
Journal:  J Dent Res       Date:  2018-02-08       Impact factor: 6.116

Review 9.  COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.

Authors:  Richard J Fagan; Andrew K Dingwall
Journal:  Cancer Lett       Date:  2019-05-22       Impact factor: 8.679

10.  Comparative analysis of lung and blood transcriptomes in mice exposed to multi-walled carbon nanotubes.

Authors:  Timur O Khaliullin; Naveena Yanamala; Mackenzie S Newman; Elena R Kisin; Liliya M Fatkhutdinova; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2020-01-22       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.